Minimum Effective Dose of Chlorantraniliprole and Chromafenozide to Control Oil Palm Bunch Moth Tirathana mundella Walker

The bunch moth, Tirathaba mundella is one of the leading pests in oil palm estates established on peatland. Severely infested male inflorescences usually would fail reaching anthesis. Reduction in the number of inflorescences at anthesis stage would suggest less food source and breeding ground for oil palm pollinating weevils, Elaeidobius kamerunicus, thus, affecting the fruiting percentage of oil palm and its yield. Despite to be less detrimental to the environment, biopesticide usages in the field is losing favour due to its slower rate of kill compared with conventional chemical pesticides, shorter persistence in the environment and susceptibility to unfavourable environmental conditions. The use of high host specificity chemical pesticides, such as chlorantraniliprole and chromafenozide are gaining popularity in pest management regimes. In this study, the optimum dose for chlorantraniliprole and chromafenozide in controlling T. mundella was assessed to provide valuable information for sustainable oil palm pest management. Several dosages of pesticide were evaluated for their effectiveness against T. mundella in a 7-year-old oil palm estate for six months. Based on the results obtained, application of 30 g or 40 g active ingredient (a.i.) per ha chlorantraniliprole were recommended to provide the longest protection period. To make plan for an effective pest management that could reduce material and labour cost per ha as well as the risks in developing pesticide resistance among pest, 30 g a.i per ha of chlorantraniliprole is recommended to be rotated with 25 g a.i. per ha chromafenozide for a total of four rounds in a year.

Post feeding protection from Bilimbi to Motile Aeromonas Septicemia disease in African Catfish

Bilimbi (Averrhoa bilimbi) is plant medicinal used to control fish diseases both prevention and treatment. This study aims to determine the protection period of bilimbi-fed which different duration in catfish to enhance catfish (Clarias sp.) immunity in order to protect fish from Aeromonas hydrophila infection. The Randomized Block Design Factorial (RBDF) with 2 factors was used in this experimental. The first factor (A) was the period of feeding containing bilimbi juice consisting of 3 treatments, namely 0 days (P0), 7 days (P1), and 14 days (P2). The second factor (B) was the protection period after the administration of bilimbi juice to the infection of A. hydrophila bacteria consisting of 3 treatment, 5 days (T5), 10 days (T10), and (T15). This research was conducted at the Laboratory of Aquaculture Experiment Pond, Faculty of Agriculture, Sriwijaya University in October-December 2018. The parameters observed included prevalence of infection, growth, survival, feed efficiency and water quality. The result revealed that by giving 300 mL.kg-1 of bilimbi juice with different periods significantly affected the period of fish protection for A. hydrophila infection. The best prevalence value was 3,33% (P2T5), and the best survival of the fish before infection was 94,17% (P2), while the best fish survival post infection was 100% (P2T5), the best feed efficiency value was 56,47% (P2), water quality under experiment were 26-29,70C for temperature, pH 6.8-7.7, dissolved oxygen 4.35-5.37 mg/L and ammonia 0.09-0.21 mg/L.Keywords:Averrhoa bilimbiAeromonas hydrophilaEthnomedicinal plantFish immunityMotile Aeromonas Septicemia

Symptomatic recurrence of SARS-CoV-2 infection in healthcare workers recovered from COVID-19

There is rising concern that patients who recover from COVID-19 may be at risk of recurrence. Increased rates of infection and recurrence in healthcare workers could cause the healthcare system collapse and a further worsening of the COVID-19 pandemic. Herein, we reported the clinically symptomatic recurrent COVID-19 cases in the two healthcare workers who treated and recovered from symptomatic and laboratory confirmed COVID-19. We discuss important questions in the COVID-19 pandemic waiting to be answered, such as the protection period of the acquired immunity, the severity of recurrence and how long after the first infection occurs. We aimed to emphasize that healthcare workers should continue to pay maximum attention to the measures without compromising.

Prevention and Control of Tuberculosis Relying on a Tuberculosis Dynamic Model Based on the Cases of American

Background: Tuberculosis (TB) which is a preventable and curable disease, is claimed as the second largest number of fatalities and there are 9,025 cases reported in the United State in 2018. Many researches have done a lot of research and achieved remarkable results, but TB is also a serious problem for human being.The study is a further exploration. Methods: In the paper, we propose a new dynamic model to study the transmission dynamics of TB, then use global differential evolution and local sequential quadratic programming (DESQP) optimization algorithm to estimate parameters of the model. Finally, we use Latin hypercube sampling (LHS) and partial rank correlation coefficients (PRCC) to analyze the influence of parameters on the basic reproduction number (R0) and the total infectious (including the diagnosed, undiagnosed and incomplete treatment infectious), respectively. Results: By the research, the basic reproduction is computed as 2.3597 which means TB will be epidemic in US. The diagnosed rate is 0.6082 which means the undiagnosed will be diagnosed after 1.6442 years. The diagnosed will be recovered with an average of 1.9912 years, especially, some diagnosed will end the treatment after 1.7550 years, for some reasons. By the study, it’s shown that there are 2.4% of the recovered will be reactivated and 13.88% of the newborn will be vaccination. However, the immunity will be lose after about 19.6078 years. Conclusion: Through the results of this study, we give some suggestions to help prevent and control the TB epidemic in the United State, such as prolonging the protection period of the vaccine by developing new and more effective vaccines to prevent TB, using the chemoprophylaxis for incubation patients to prevent their conversion into active TB; raising people’s awareness of prevention and control of TB and treatment after illness; isolation treatment for the infected to reduce the spread of TB. According to the latest report, in the announcement came at the first WHO Global Ministerial Conference on Ending Tuberculosis in the Sustainable Development Era, we predict that it’s difficult to control TB in 2030.

Analytical comparison of Soliris® and its biosimilar, PRK-001

Soliris® (Eculizumab) was approved by regulatory authorities as the first drag for treatment of orphan disease, paroxysmal nocturnal hemoglobinuria, in 2007. Later its use was extended for treatment of atypical hemolytic-uremic syndrome and myasthenia gravis. The high cost, the unavailability of therapy for a number of patients, as well as the expiration of the patent protection period for Soliris®, these factors became the prerequisite for the development of biosimilar medicinal products. Here, comparative analysis of PRK-001 (LLC «Pharmapark») and reference drag product, Soliris® (Alexion Pharmaceuticals, USA), was carried out. Physicochemical biosimilarity assessment has shown complete comparability of both products in terms of protein sequence as well as higher order structures. Post-translation modifications as well as impurity profile were the same too. Neither biosimilar nor reference product had impurity amount exceeding threshold. Biological properties of the reference product and biosimilar were the same. Since the comparability of the both drags has been proven, it can be assumed that PRK-001 is biosimilar of Soliris®. Eculizumab, Soliris, paroxysmal nocturnal hemoglobinuria, physicochemical comparison, post-translational modifications, biosimilar, drag product

Aesthetic Performance Products as a Basis For Non Novelty of Industrial Design Based on The Public Domain Principle

Comparative products are very important and must be considered about it because, Industrial Design assesses the performance of products that can be proven from evidence that can be seen or assessed by clear eye such as photographic evidence, catalogs or other evidence that can be proved bye Industrial Design which has existed before. Industrial design is based on its external appearance which does not have an aesthetic impression and contradicts Article 1 point 1 of the Industrial Design Law and article 25 Paragraph 1 of the TRIPs agreement, which is form creation, solely for function or technical configuration. Aesthetically cannot be registered. In the absence of aesthetic elements, the product performance can be used as the basis for the absence of new industrial designs based on the principle of "Public Domain", considering the aesthetic elements are one of the requirements of an item that can be categorized as Industrial Design. In the other hand, the protection period has expired and became a "Public Domain" then it can be registered as an Industrial Design if it packed with an aesthetic elements. If an item does not have an aesthetic impression, it can be ascertained that the item is not an industrial design and can be possible not to have novelty and become public property. Aesthetic impressions do not contradict with the laws and regulations, but this is an important requirement so the design can be categorized as an industrial design. In ordinance No. 31 in 2000 concerning Industrial Design itself does not limit of the notion novelty and aesthetics so, the multiple interpretations are often occur.

Bankruptcy protection duration and outcome of Canadian public firms

PurposeThe purpose of this paper is to investigate the determinants of bankruptcy protection duration of Canadian public firms, and also investigate the duration for various bankruptcy outcomes including the liquidation and re-emergence of bankrupt firms.Design/methodology/approachThis study uses data on all Canadian public firms that applied for bankruptcy protection over the period 1992–2014. The authors mainly apply duration and survival analyses to draw the main conclusions.FindingsThe authors find that larger and older firms with more complicated structures and issues to settle tend to remain under protection from creditors longer, and also ascertain that the fate of relatively successful companies is determined faster. Moreover, the authors report that it takes less time to achieve a final solution for firms under bankruptcy protection when interest rates are increasing and the term spread is high. Finally, firms that file for protection under the Companies’ Creditors Arrangement Act (CCAA) spend longer restructuring than firms that file under the Bankruptcy and Insolvency Act.Research limitations/implicationsThe paper investigates only publicly listed firms. The data on private firms that are required to conduct the research are not available.Practical implicationsVarious stakeholders including regulators can predict the bankruptcy protection period using the paper’s findings. Depending on the desired outcomes (reduce uncertainly, safeguard jobs or protect creditors’ rights), specific rules can be followed.Originality/valueTo the authors; knowledge, this is the first paper that investigates the Canadian bankruptcy protection duration. It uses the unique Canadian framework to infer the determinants of bankruptcy protection duration and bankrupt firms’ outcomes.

DEFINITION OF THE PATENT AND THE PERIOD OF PROTECTION.

Patent is a special right granted by the State to the inventor for the results of his invention in the field of technology, for a certain period of time implementing the invention himself or giving his approval to others to carry it out, types of patents namely patents and simple patents. Patents are exclusive rights granted by the state to inventors for the results of their inventions in the field of technology which for a certain period of time carry out their own or give approval to other parties to implement them while Simple Patents are any inventions in the form of new products or tools and practical utility the form, configuration, construction, or component can obtain legal protection in the form of a simple patent Patent Protection Period As known in Article 8 paragraph 1 of Law No. 14 of 2001 concerning Patents, the patent is granted for a period of 20 (twenty years) from the date of receipt and the period cannot be extended, whereas for a simple patent given for a period of 10 (ten years) from the date of receipt and the period cannot be extended. If the patent protection period has expired, an event will become a public domain so that other parties can freely produce and sell it. The rules regarding the validity period of the patent are intended so that no party can continuously control the entire industry so that it is feared that it can harm the community and the trading system.